Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The synthetic antibacterial drug clofoctol (CFT) has long been used to treat respiratory tract infections in Europe. In recent years, the drug was found to target two biologically important proteins, the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras protein (UNR). These interactions are at the origin of the antitumor activity of CFT, recently evidenced in prostate cancer and neuroglioma. Drug-protein binding models provide a structural basis to guide the design of more potent anticancer compounds. A renewed interest in CFT can be anticipated for the treatment of cancers, and possibly Coronavirus 2019 (COVID-19). Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Christian Bailly, Gérard Vergoten. A new horizon for the old antibacterial drug clofoctol. Drug discovery today. 2021 May;26(5):1302-1310

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33581321

View Full Text